β-receptor blocking drugs in present cardiologic therapy Review article

Main Article Content

Adrian Lewandowski
Marek Kuch

Abstract

β-receptor blocking drugs are one of the most important medications in cardiology. This article describes basic mechanisms of their activity and indications for using them in specific disorders of cardio-vascular system.

Downloads

Download data is not yet available.

Article Details

How to Cite
Lewandowski , A., & Kuch , M. (2007). β-receptor blocking drugs in present cardiologic therapy. Cardiology in Practice, 1(2), 91-99. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1714
Section
Articles

References

1. Kostowski W., Herman Z.S.: Leki beta-adrenolityczne oraz leki blokujące kanały wapniowe. W: Farmakologia – podstawy farmakoterapii. Wydawnictwo Lekarskie PZWL, Warszawa 2004: 509-530.
2. Dubiel J.S., Heba G.: Leki β-adrenolityczne w leczeniu stabilnej choroby wieńcowej. W: Leki β-adrenolityczne w choroba ch układu sercowo-naczyniowego. Grodzicki T., Januszewicz A., Opolski G. (red.) Via Medica 2004.
3. Expert consensus document on beta-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European society of cardiology. Task Force Members, Jose Lopez-Sendon, Karl Swedberg, John McMurray et al. Eur Heart J 2004, 25: 1341-1362.
4. Filipiak K.J., Grabowski M., Opolski G.: Farmakologia kliniczna leków β-adrenolitycznych. W: Leki β-adrenolityczne w chorobach układu sercowo-naczyniowego. Grodzicki T., Januszewicz A., Opolski G. (red.) Via Medica 2004.
5. Frishman W.H.: Multifactorial actions of beta-adrenergic-blocking drugs in ischemic heart disease: current concepts. Circulation 1983, 67 (suppl. I): 11-8.
6. Freemantle N., Cleland J., Young J. et al.: Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999, 318: 1730-1737.
7. Yusuf S., Lessem J., Pet J. et al.: Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials. J Hypertens 1993, 11 (suppl. 4): 61-S73.
8. Harjai K.J., Stone G.W., Boura J. et al.: Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003, 91: 655-60.
9. Gottlieb S., McCarter R., Vogel R. et al.: Effect of beta-blockade on mortality among high risk patients after myocardial infarction. National Cooperative Cardiovascular Project. N Engl J Med 1998, 338: 489-97.
10. Yusuf S., Witte J., Friedman L.: Overview of results of randomized trials in heart disease: unstable angina, heart failure, primary prevention with aspirin and risk factor modifications. JAMA 1988, 260: 2259-63.
11. ACC/ AHA 2002 guideline update for management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of cardiology/ American Heart Association Task force on Practice Guidelines (Committee on Management of Patients With Unstable Angina).
11a. Sznajderman M.: Brytyjskie wytyczne postępowania w nadciśnieniu tętniczym – aktualizacja 2006. Med Prakt 2006.
12. The Seventh Report of the Joint National Committee on Prevention, Dtection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003, 289: 2560-2575.
13. MERIT-HF study group. Effect of metoprolol CR/ XL in chronic heart failure. Metoprolol CR/ XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353: 2001- 7.
14. CIBIS-II investigators and committees. The cardiac insufficiency bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353: 9-13.
15. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic failure: results of the carvediliol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002, 106: 2194- 2199.
16. Dargie H.J., Colucci Y., Ford I. et al.: Effect of Carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357: 1385-1390.
17. McMurray J., Kober L., Robertson M. et al.: Antiarrhythmic Effect of Carvedilol After Acute Myocardial Infarction Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) Trial. J Am Coll Cardiol. 2005, 45: 525-530.
18. Syska-Sumińska J. Kuch M.: Beta-adrenolityki w niewydolności serca. W: Farmakologia Kliniczna. Dłużniewski M., Mamcarz A., Krzyżak P. (red.) Wydawnictwo AM 2002.
19. Haas S.J., Vos T., Gilbert R.E. et al.: Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large scale clinical trials. Am. Heart J. 2003, 146: 848-53.
20. Malmberg K.: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI study group. BMJ 1997, 314: 1512-5.
21. Filipiak K.J., Marchel M., Kownacki Ł.: Aktualne standardy farmakoterapii stabilnej choroby wieńcowej – implikacje ostatnio opublikowanych zaleceń. Standary Med 2004, 17 (suppl): 99-107.
22. Opolski G., Filipiak K.J., Poloński L.: Ostre zespoły wieńcowe. Wydawnictwo Urban&Partner, Wrocław 2002.
23. Rdzanek A., Wilczyńska J., Rdzanek H.: Pacjent po PCI – postępowanie terapeutyczne w opiece ambulatoryjnej. Standardy Med. 2004, 17 (supl.): 68-80.